A medicine commonly used for high blood pressure may do more than relax blood vessels. In this study, it also quieted several alarm signals from immune cells when inflammation was already switched on. Benidipine hydrochloride is a medication frequently used by patients with high blood pressure.

It acts by blocking channels that help blood vessels tighten, but its effects on macrophages, immune cells that help drive inflammation, had not been investigated. The study examined whether benidipine hydrochloride changed inflammatory activity in mouse macrophage cells.

The central finding was a two-part pattern: the medicine did not make the cells produce inflammatory signals on its own, but it reduced those signals when the cells were already stimulated. That is why the study describes an anti-inflammatory activity. The question was whether benidipine hydrochloride changed immune activity in mammalian macrophages when the cells were resting and when they were exposed to a substance that stimulates inflammation.

That distinction matters in clinical use, because knowing whether BH has pro- or anti-inflammatory activity is important for using it effectively. The study examined BH's immunostimulatory and immunomodulatory activity in macrophages under two conditions: without LPS, and with LPS as a stimulant.

If it suppresses inflammation, the study says patients with high blood pressure and acute inflammation might not need an additional anti-inflammatory drug, helping prevent unwanted side effects. The cells were tested in two situations: benidipine hydrochloride was given by itself, and it was given together with a substance used to activate inflammation.

The comparison included cells exposed only to the inflammatory stimulus and cells that received no treatment, so the medicine’s effect could be judged against both conditions. To test whether the medicine could change an active immune response, it was given together with the inflammatory stimulus to the macrophages.

After the cells had been left for a period of time, the surrounding liquid was checked for one inflammatory signal. Compared with cells that received only the inflammatory stimulus, cells exposed to benidipine hydrochloride produced substantially less of that signal.

The result was consistent with anti-inflammatory activity. The same pattern appeared for another inflammatory signal: benidipine hydrochloride did not stimulate the macrophages to produce it when the inflammatory stimulus was absent. But when the cells were activated and then treated with benidipine hydrochloride, production of that signal decreased compared with cells receiving only the inflammatory stimulus.

A further test found that benidipine hydrochloride was not able to stimulate production of another inflammatory signal by itself. When the cells were activated with the inflammatory stimulus, however, benidipine hydrochloride significantly suppressed production of that signal.

The experiment was designed to mimic ongoing inflammation in the body by giving benidipine hydrochloride to macrophages in the presence of an inflammatory stimulus. Across the tested signals, production decreased substantially when the medicine was present during activation of the cells.

The study says this could mean that patients with high blood pressure and inflammatory reactions might be prescribed benidipine hydrochloride alone, rather than needing an additional anti-inflammatory drug. That could simplify treatment and help prevent excessive dosing and possible side effects.

The findings suggest that benidipine hydrochloride may reduce inflammatory activity in immune cells without activating those cells by itself. That could matter when high blood pressure and inflammation occur together, but this laboratory result is not yet a treatment recommendation.